FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.3% for Plaque Psoriasis in Children as Young as Age 2
Key Dates
What Happened
On June 29, 2026, the FDA approved Arcutis's supplemental NDA to expand ZORYVE cream 0.3% for plaque psoriasis, including intertriginous areas, to pediatric patients down to age 2. The label had previously gone down to age 6. Arcutis says the product is the first once-daily, steroid-free topical approved for plaque psoriasis in this age group, with no duration-of-use limits and suitability for use anywhere on the body.
Who It Affects
This matters to pediatric dermatology practices, children's hospitals, specialty pharmacies, and families managing chronic inflammatory skin disease in very young children. It also matters to companies building pediatric specialty-care coordination, access, and adherence infrastructure around branded therapies that move from older pediatric cohorts into toddlers and preschool-age populations.
Business Implications
This is another data point in the pediatric label wave PHD has been tracking: established adult or older-pediatric franchises are still moving downward into younger age bands through formal pediatric studies and supplemental FDA work. For operators, the commercial story is not only the label expansion itself but the follow-on access mechanics: prior authorization, specialty-pharmacy routing, caregiver education, and persistence support for long-duration chronic treatment. It also reinforces the logic behind tracking incumbents like Arcutis in pediatric specialty categories where startup value may accrue more in the operational layer than in the molecule.